This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Pharosgen Co., Ltd. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Ha Kyeong Lee: Innovator in Doppel-Targeting Antibodies
Introduction
Ha Kyeong Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of doppel-targeting antibodies. His work focuses on addressing critical health issues associated with pathological angiogenesis.
Latest Patents
Ha Kyeong Lee holds 1 patent for his innovative doppel-targeting antibodies. This patent describes molecules that are useful for inhibiting pathological angiogenesis and treating various diseases and conditions, including tumors, cancers, atherosclerosis, tuberculosis, asthma, and pulmonary arterial hypertension (PAH). The patent also outlines methods for detecting doppel expression in subjects, showcasing the potential impact of his work on medical diagnostics and therapeutics.
Career Highlights
Ha Kyeong Lee is currently associated with Pharosgen Co., Ltd., where he continues to advance his research and development efforts. His expertise in biotechnology and antibody engineering has positioned him as a key figure in the industry.
Collaborations
Ha Kyeong Lee collaborates with notable colleagues, including Youngro Byun and So Young Choi. Their combined efforts contribute to the innovative research environment at Pharosgen Co., Ltd.
Conclusion
Ha Kyeong Lee's work in developing doppel-targeting antibodies represents a significant advancement in the fight against diseases related to pathological angiogenesis. His contributions are poised to make a lasting impact on medical science and patient care.